Intersect ENT is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The Company markets the first and only drug-releasing sinus implants, PROPEL and PROPEL mini, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis. The products release an advanced steroid with anti-inflammatory properties directly into the sinus lining, then dissolve, maintaining the open passages created in ethmoid sinus surgery. In addition, Intersect ENT is pursuing clinical trials designed to support expanded indications and to assess two new investigational drug-eluting implants to provide ENT physicians with additional options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
Type
Public
HQ
Menlo Park, US
Founded
2003
Size (employees)
303 (est)
Intersect ENT was founded in 2003 and is headquartered in Menlo Park, US
Report incorrect company information

Key People/Management at Intersect ENT

Lisa Earnhardt

Lisa Earnhardt

President & CEO
Monika De Martini

Monika De Martini

CFO
Robrt Binney

Robrt Binney

Vice President of Sales
Amy Wolbeck

Amy Wolbeck

Vice President, Regulatory Affairs and Quality
Susan P Stimson

Susan P Stimson

Vice President of Marketing
Rich Kaufman

Rich Kaufman

Senior Vice President and Chief Operating Officer

Intersect ENT Office Locations

Intersect ENT has an office in Menlo Park
Menlo Park, US (HQ)
1555 Adams Dr
Show all (1)
Report incorrect company information

Intersect ENT Financials and Metrics

Intersect ENT Financials

Intersect ENT's revenue was reported to be $96.30 m in FY, 2017
USD

Revenue (Q1, 2018)

24.7 m

Gross profit (Q1, 2018)

19.2 m

Gross profit margin (Q1, 2018), %

77.8%

Net income (Q1, 2018)

(6.1 m)

EBIT (Q1, 2018)

(6.5 m)

Market capitalization (14-Jun-2018)

1.1 b

Closing share price (14-Jun-2018)

37

Cash (31-Mar-2018)

10.5 m
Intersect ENT's current market capitalization is $1.1 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

38.6 m61.6 m78.7 m96.3 m

Revenue growth, %

60%28%

Cost of goods sold

10.2 m12.3 m13 m15.5 m

Gross profit

28.4 m49.3 m65.7 m80.8 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

15.2 m14.2 m16.7 m19.3 m18.5 m20.5 m24 m22.3 m24.7 m

Cost of goods sold

2.9 m2.9 m3.2 m3.1 m2.8 m2.9 m3.7 m3.8 m5.5 m

Gross profit

12.3 m11.4 m13.5 m16.2 m15.7 m17.6 m20.3 m18.5 m19.2 m

Gross profit Margin, %

81%80%81%84%85%86%85%83%78%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

13.4 m34.8 m9.9 m19.8 m

Accounts Receivable

8.3 m11.5 m14.4 m16.6 m

Inventories

951 k1.5 m1.3 m8.5 m

Current Assets

60.3 m141.2 m125.3 m130.3 m
Quarterly
USDQ3, 2017Q1, 2018

Cash

10.5 m

Accounts Receivable

11.7 m14.3 m

Inventories

1.6 m8.5 m

Current Assets

128.1 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(18.4 m)(26.6 m)(25.2 m)(16.4 m)

Depreciation and Amortization

1.2 m1.5 m

Inventories

(541 k)(544 k)(1.7 m)(2.9 m)

Accounts Payable

645 k(230 k)1.2 m203 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.8 m)(9.7 m)(8.2 m)(6 m)(6.2 m)(6.7 m)(4.3 m)

Inventories

2.8 m2.7 m2.8 m3.2 m3.7 m4.9 m5.9 m7.2 m7.1 m8 m1.6 m

Accounts Payable

2.7 m2.1 m2 m2.5 m3.2 m2.9 m2.6 m3.2 m2.3 m2.5 m2.5 m
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Intersect ENT Operating Metrics

Intersect ENT's Patients was reported to be 150 k in FY, 2016.
FY, 2016

Facilities

1

Patents (US)

30

Patients

150 k

Trademarks (US)

4
Show all operating metrics
Report incorrect company information

Intersect ENT Online and Social Media Presence

Embed Graph
Report incorrect company information